DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Software
Author Program NEWCreate Narrative
MTLS logo

Materialise NV Stock Price

NasdaqGS:MTLS Community·US$449.6m Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 37 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MTLS Share Price Performance

US$7.77
2.37 (43.89%)
​
US$8.99
Fair Value
US$7.77
2.37 (43.89%)
13.6% undervalued intrinsic discount
US$8.99
Fair Value
Price US$7.77
AnalystConsensusTarget US$8.99
AnalystHighTarget US$10.01
AnalystLowTarget US$8.06
Thu, 4 Sep 25
Fair ValueUS$8.99
Share Pricen/a

MTLS Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$8.99 13.6% undervalued intrinsic discount

Personalized Healthcare And Automation Will Unlock Future Markets

0users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$10.01 22.4% undervalued intrinsic discount

Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$8.06 3.5% undervalued intrinsic discount

Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MTLS logo
Materialise
3.5% undervalued intrinsic discount

Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
MTLS logo
Materialise
22.4% undervalued intrinsic discount

Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 1 Jun
Read Narrative
MTLS logo
Materialise
13.6% undervalued intrinsic discount

Personalized Healthcare And Automation Will Unlock Future Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 6 May 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
MTLS logo

MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations

Fair Value: US$8.06 3.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
MTLS logo

Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability

Fair Value: US$10.01 22.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
MTLS logo

Personalized Healthcare And Automation Will Unlock Future Markets

Fair Value: US$8.99 13.6% undervalued intrinsic discount
24 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
3 Rewards
View Full Analysis

Materialise NV Key Details

€272.8m

Revenue

€116.7m

Cost of Revenue

€156.1m

Gross Profit

€142.9m

Other Expenses

€13.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 28, 2026
0.23
57.23%
4.84%
20.9%
View Full Analysis

About MTLS

Founded
1990
Employees
2556
CEO
Brigitte de Vet-Veithen
WebsiteView website
www.materialise.com

Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.

Recent MTLS News & Updates

User avatar
Narrative Update • Sep 03

MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations

Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.
Seeking Alpha • Aug 31

Materialise: A High-Margin Medical Business Hiding In Plain Sight

Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking Alpha
Analysis Article • Aug 30

Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92

It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...

Recent updates

No updates

Materialise NV Competitors

BBAI logo

BigBear.ai Holdings

Symbol: NYSE:BBAI
Market cap: US$1.3b
EFOR logo

Everforth

Symbol: NYSE:EFOR
Market cap: US$1.3b
APPS logo

Digital Turbine

Symbol: NasdaqCM:APPS
Market cap: US$1.3b
CXM logo

Sprinklr

Symbol: NYSE:CXM
Market cap: US$1.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide